Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Oncogene|November 28, 2018
ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumorsG Vargas, M Bouchet, L Bouazza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
Breast Cancer Research and Treatment|January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohortM Bringuier, M Carton, C Levy, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
British Journal of Cancer|June 25, 2024
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancerF Poumeaud, M Morisseau, L Cabel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 4